Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henit Yanai

Showing results (91-100 of 129) with videos related to

Pageof 13
Sort By:
United European Gastroenterology Journal|August 19, 2020
Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort studyNathaniel Aviv Cohen, Nikolas Plevris, Uri Kopylov, et al.
Journal of Crohn'S & Colitis|December 18, 2014
Prognosis of primary sclerosing cholangitis in israel is independent of coexisting inflammatory bowel DiseaseHenit Yanai, Shay Matalon, Amir Rosenblatt, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 3, 2018
Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experienceUri Kopylov, Irit Avni-Biron, Yulia Ron, et al.
The Lancet. Gastroenterology & Hepatology|November 5, 2021
The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trialHenit Yanai, Arie Levine, Ayal Hirsch, et al.
Inflammatory Bowel Diseases|February 9, 2017
Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World ExperienceUri Kopylov, Yulia Ron, Irit Avni-Biron, et al.
Journal of Clinical Medicine|April 13, 2023
Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort StudyAhmad Albshesh, Lian Bannon, Tali Sharar Fischler, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 10, 2021
Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in IsraelIrit Avni-Biron, Ariella Bar-Gil Shitrit, Benjamin Koslowsky, et al.
Alimentary Pharmacology & Therapeutics|September 28, 2022
Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort studyIrit Avni-Biron, Tali Mishael, Eran Zittan, et al.
Journal of Crohn'S & Colitis|March 3, 2022
Mental Health, Work Presenteeism, and Exercise in Inflammatory Bowel DiseaseMartina Sciberras, Konstantinos Karmiris, Catarina Nascimento, et al.
United European Gastroenterology Journal|March 28, 2020
Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli studyAriella Bar-Gil Shitrit, Ami Ben-Ya'acov, Matan Siterman, et al.
Pageof 13

Showing results (91-100 of 129) with videos related to

Sort By:
Pageof 13
United European Gastroenterology Journal|August 19, 2020
Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort studyNathaniel Aviv Cohen, Nikolas Plevris, Uri Kopylov, et al.
Journal of Crohn'S & Colitis|December 18, 2014
Prognosis of primary sclerosing cholangitis in israel is independent of coexisting inflammatory bowel DiseaseHenit Yanai, Shay Matalon, Amir Rosenblatt, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 3, 2018
Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experienceUri Kopylov, Irit Avni-Biron, Yulia Ron, et al.
The Lancet. Gastroenterology & Hepatology|November 5, 2021
The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trialHenit Yanai, Arie Levine, Ayal Hirsch, et al.
Inflammatory Bowel Diseases|February 9, 2017
Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World ExperienceUri Kopylov, Yulia Ron, Irit Avni-Biron, et al.
Journal of Clinical Medicine|April 13, 2023
Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort StudyAhmad Albshesh, Lian Bannon, Tali Sharar Fischler, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 10, 2021
Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in IsraelIrit Avni-Biron, Ariella Bar-Gil Shitrit, Benjamin Koslowsky, et al.
Alimentary Pharmacology & Therapeutics|September 28, 2022
Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort studyIrit Avni-Biron, Tali Mishael, Eran Zittan, et al.
Journal of Crohn'S & Colitis|March 3, 2022
Mental Health, Work Presenteeism, and Exercise in Inflammatory Bowel DiseaseMartina Sciberras, Konstantinos Karmiris, Catarina Nascimento, et al.
United European Gastroenterology Journal|March 28, 2020
Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli studyAriella Bar-Gil Shitrit, Ami Ben-Ya'acov, Matan Siterman, et al.
Pageof 13